Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Dan Su,Ruobing Wang,Guangyu Chen,Chen Ding,Yueze Liu,Jinxin Tao,Yuanyang Wang,Jiangdong Qiu,Wenhao Luo,Guihu Weng,Gang Yang,Taiping Zhang

DOI: https://doi.org/10.1158/0008-5472.26711161.v1

2024-01-01

Abstract:Supplementary Fig. S5

What problem does this paper attempt to address?

FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Dan Su,Ruobing Wang,Guangyu Chen,Chen Ding,Yueze Liu,JInxin Tao,Yuanyang Wang,Jiangdong Qiu,Wenhao Luo,Guihu Weng,Yang Gang,Taiping Zhang

DOI: https://doi.org/10.1158/0008-5472.can-23-3638

IF: 11.2

2024-05-23

Cancer Research

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death worldwide, primarily due to its rapid progression. The current treatment options for PDAC are limited, and a better understanding of the underlying mechanisms responsible for PDAC progression is required to identify improved therapeutic strategies. Here, we identified FBXO32 as an oncogenic driver in PDAC. FBXO32 was aberrantly upregulated in PDAC, and high FBXO32 expression was significantly associated with an unfavorable prognosis in PDAC patients. FRG1 deficiency promoted FBXO32 upregulation in PDAC. FBXO32 promoted cell migration and invasion in vitro and tumor growth and metastasis in vivo. Mechanistically, FBXO32 directly interacted with eEF1A1 and promoted its polyubiquitination at the K273 site, leading to enhanced activity of eEF1A1 and increased protein synthesis in PDAC cells. Moreover, FBXO32-catalyzed eEF1A1 ubiquitination boosted the translation of ITGB5 mRNA and activated FAK signaling, thereby facilitating focal adhesion assembly and driving PDAC progression. Importantly, interfering with the FBXO32-eEF1A1 axis or pharmaceutical inhibition of FAK by defactinib, an FDA-approved FAK inhibitor, substantially inhibited PDAC growth and metastasis driven by aberrantly activated FBXO32-eEF1A1 signaling. Overall, this study uncovers a mechanism by which PDAC cells rely on FBXO32-mediated eEF1A1 activation to drive progression and metastasis. FBXO32 may serve as a promising biomarker for selecting eligible PDAC patients for treatment with defactinib.

oncology
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419837.v1

2023-01-01

Abstract:Supplementary figure S5. DAC treatment did not increase the risk of osteosarcoma proliferation.
Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419840

2023-01-01

Abstract:Supplementary figure S4. Immunofluorescence on intratumoral lymphocytes and qRT-PCR assays on TH1-type chemokine expression
Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Xue Meng,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Li,Xiu‐Ping Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419846.v1

2023-01-01

Abstract:Supplementary figure S2. Gating strategies for flow cytometry analyses.
Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419843.v1

2023-01-01

Abstract:Supplementary figure S3. Flow cytometry analyses of tumor draining lymph nodes.
Supplementary Figure from EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis Via Activating FAK Signal

Haojie Li,Xuhong Fu,Junjie Zhao,Chen Li,Lingmeng Li,Peiyan Xia,Jianping Guo,Wenyi Wei,Rong Zeng,Jiarui Wu,Yihong Sun,Liyu Huang,Xuefei Wang

DOI: https://doi.org/10.1158/1541-7786.22527882

2023-01-01

Abstract:Supplementary Figure from EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal
Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Xiaomao Guo,Zheng Li,Jianxin Jiang,Yan Zhao,Xin Wang,Ming Shen,Feng Zhu,Rui Tian,Changcheng Shi,Meng Xu,Xu Li,Pingfa Feng,Hang Zhang,Yechen Feng,Yuan Xie,Xiaodong Xu,Jia Wang,Ruizhi He,Chencheng Xie,Jun Hu,Dawei Ye,Min Wang,Renyi Qin

DOI: https://doi.org/10.1158/1078-0432.22459142.v1

2023-01-01

Abstract:Figure S5: IL-18 promotes PC cell proliferation, invasion and metastasis.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Supplementary Data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

Rui Sun,Hong-Yan Xie,Jin-Xian Qian,Yan-Ni Huang,Fan Yang,Fang-Lin Zhang,Zhi-Min Shao,Da-Qiang Li

DOI: https://doi.org/10.1158/0008-5472.22419813.v1

2023-01-01

Abstract:The Supplementary Information includes: Figure S1. The effects of FBXO22 on breast cancer cell proliferation and anchorage-independent 3D growth. Figure S2. FBXO22 promotes xenograft tumor growth of MDA-MB-231 cells in vivo. Figure S3. FBXO22 suppresses cell migration and invasion. Figure S4. The effects of FBXO22 on the expression levels of EMT markers. Figure S5. The effects of FBXO22 on the mRNA levels of SNAIL. Figure S6. Schematic diagram of the structural domains of FBXO22 and SNAIL proteins. Figure S7. Phosphorylation of SNAIL by GSK3β affects its stability and subcellular localization. Figure S8. The mutation pattern of FBXO22 in breast cancer. Figure S9. The effects of deletion of F-box domain or W52R mutation on subcellular localization of FBXO22 and protein stability of SNAIL. Figure S10. The proposed working model. Table S1. Characterization of clincopathological features of 164 primary breast cancer patients. Table S2. siRNA target sequences for GSK3β. Tables S3. Primers used for molecular cloning of expression vectors. Tables S4. Information of expression vectors used in this study. Tables S5. Information for primary antibodies used in this study. Tables S6. Primers used for qPCR analysis. Table S7. Correlation between FBXO22 expression and clincopathological factors in 164 primary breast cancer patients. Table S8. Multivariate analysis of clincopathological factors for OS and DFS in 164 primary breast cancer patients.
FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2

Jingsheng Ma,Yajun Wu,Shibao Cheng,Wentao Yang,Lin Zhong,Qigen Li,Lu Fang

DOI: https://doi.org/10.1007/s10620-022-07780-6

Abstract:Background: Dysregulation of ubiquitin ligases plays a crucial role in the development and progression of various human tumors. F-box only protein 22 (FBXO22), an F-box E3 ubiquitin ligase, has been reported to participate in diverse aspects of cancer progression. However, the clinical significance and biological function of FBXO22 in pancreatic cancer remain poorly understood. Aims: This study aimed to investigate the role of FBXO22 in promoting pancreatic cancer growth. Methods: FBXO22 expression was detected in pancreatic cancer and adjacent normal tissues using qRT-PCR, western blotting, and immunohistochemistry. Ectopic expression and knockdown of FBXO22 were performed to measure the impact on pancreatic cancer cells growth by CCK-8, colony formation, and tumorigenicity assay. Bioinformatics analysis uncovered the potential correlation between FBXO22 and various signaling pathways. Western blotting and immunoprecipitation were performed to identify FBXO22-interacting proteins. Results: We observed that FBXO22 was upregulated in samples obtained from patients with pancreatic cancer compared with its levels in the adjacent normal tissues, and an elevated FBXO22 level was obviously associated with poor prognosis among patients with pancreatic cancer. FBXO22 knockdown impaired pancreatic cancer cell growth both in vitro and in vivo, whereas FBXO22 overexpression accelerated pancreatic cancer cell growth. Furthermore, we found that FBXO22 contributed to pancreatic cancer cell growth by deactivating the Hippo pathway. Mechanistically, FBXO22 directly interacts with and destabilizes the large tumor suppressor 2 (LATS2), which is a critical regulator of the Hippo pathway. Blocking LATS2 leads to the loss of FBXO22-mediated oncogenic effect in pancreatic cancer. Conclusions: These findings provide new insights into the upstream regulation of the Hippo pathway inactivation in pancreatic cancer growth and identify FBXO22 as a potential therapeutic target for this lethal malignant tumor.
Supplemental Fig.S2. from HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy

Tongzheng Liu,Yuan Fang,Haoxing Zhang,Min Deng,Bowen Gao,Nifang Niu,Jia Yu,SeungBaek Lee,JungJin Kim,Bo Qin,Fang Xie,Debra Evans,Liewei Wang,Wenhui Lou,Zhenkun Lou

DOI: https://doi.org/10.1158/0008-5472.22409685

2023-01-01

Abstract:Supplemental Fig.S2. HEATR1 regulates cancer cell response to chemotherapy and cell growth
Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512175.v1

2023-01-01

Abstract:FBW7 was involved in the expression and shedding of CA125
Figure S6 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Yun-Han Huang,Jing Hu,Fei Chen,Nicolas Lecomte,Harihar Basnet,Charles J. David,Matthew D. Witkin,Peter J. Allen,Steven D. Leach,Travis J. Hollmann,Christine A. Iacobuzio-Donahue,Joan Massagué

DOI: https://doi.org/10.1158/2159-8290.22535531.v1

2023-01-01

Abstract:Figure S6
Supplementary Figure 2 from Amplification and Overexpression of cttn (ems1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Man‐Li Luo,Xiaoming Shen,Yu Zhang,Wei Fang,Xin Xu,Cheng Yan,Xun Zhang,Yan Sun,Qimin Zhan,Min Wang,Ming-Rong Wang

DOI: https://doi.org/10.1158/0008-5472.22367081

2023-01-01

Abstract:Supplementary Figure 2 from Amplification and Overexpression of CTTN (EMS1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance
Supplementary Figure 3 from Amplification and Overexpression of CTTN (EMS1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Man-Li Luo,Xiao-Ming Shen,Yu Zhang,Fang Wei,Xin Xu,Yan Cai,Xun Zhang,Yun-Tian Sun,Qi-Min Zhan,Min Wu,Ming-Rong Wang

DOI: https://doi.org/10.1158/0008-5472.22367084.v1

2023-01-01

Abstract:Supplementary Figure 3 from Amplification and Overexpression of CTTN (EMS1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance
Figure S2 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Yun-Han Huang,Jing Hu,Fei Chen,Nicolas Lecomte,Harihar Basnet,Charles J. David,Matthew D. Witkin,Peter J. Allen,Steven D. Leach,Travis J. Hollmann,Christine A. Iacobuzio-Donahue,Joan Massagué

DOI: https://doi.org/10.1158/2159-8290.22535543.v1

2023-01-01

Abstract:Figure S2
FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation

Kai Chen,Yue Wang,Xingna Dai,Jingjing Luo,Shangshang Hu,Zhihui Zhou,Jinglong Shi,Xueshan Pan,Tong Cao,Jun Xia,Yuyun Li,Zhiwei Wang,Jia Ma

DOI: https://doi.org/10.1038/s41419-024-06425-y

2024-01-12

Abstract:Abstract FBXO31, a member of F-box family to comprise of SCF complex, contributes to a pivotal role in cancer progression. However, the possible involvements of FBXO31 in PC are unelucidated. Here, we reported that FBXO31 was overexpressed in PC patients, which was negatively associated with survival in PC patients. Furthermore, FBXO31 significantly enhanced growth, migration and invasion of PC cells in vitro. Consistently, FBXO31 overexpression promoted tumor growth in nude mice. Mechanistically, SIRT2 was a target of FBXO31 and interacted with FBXO31. Protein half-life and ubiquitination analysis demonstrated that FBXO31 promoted proteasome-dependent degradation of SIRT2. In addition, FBXO31 binds to sirtuin-type domain of SIRT2. Moreover, SIRT2 is required for the oncogenic role of FBXO31 in PC progression. Impressively, METTL3 induced m6A modification of FBXO31 and up-regulated FBXO31 expression, subsequently leading to SIRT2 down-regulation in PC cells. The results showed that METTL3 enhanced FBXO31 mRNA translation in YTHDF1-dependent manner. Taken together, we suggest that METTL3–FBXO31–SIRT2 axis was involved in PC tumorigenesis, which could identify new targets for PC treatment.

cell biology
Supplementary Figure S6 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Fei Huang,Qiaoni Shi,Yuzhen Li,Linlin Xu,Chi Xu,Fenfang Chen,Hai Wang,Hongwei Liao,Zai Chang,Fang Liu,Xiang H.-F. Zhang,Xin-Hua Feng,Jing-Dong J. Han,Shiwen Luo,Ye-Guang Chen

DOI: https://doi.org/10.1158/0008-5472.22420265

2023-01-01

Abstract:S208 phosphorylation is important for Smad3 nuclear accumulation
Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Hua Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125055.v1

2024-01-01

Abstract:Supplementary Video S1 is related to Figure 5 (Vehicle-only group).

Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure from EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis Via Activating FAK Signal

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2

Supplemental Fig.S2. from HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy

Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Figure S6 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Supplementary Figure 2 from Amplification and Overexpression of <i>cttn</i> (<i>ems1</i>) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Supplementary Figure 3 from Amplification and Overexpression of <i>CTTN</i> (<i>EMS1</i>) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Figure S2 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation

Supplementary Figure S6 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure from EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis Via Activating FAK Signal

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2

Supplemental Fig.S2. from HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy

Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Figure S6 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Supplementary Figure 2 from Amplification and Overexpression of &lt;i&gt;cttn&lt;/i&gt; (&lt;i&gt;ems1&lt;/i&gt;) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Supplementary Figure 3 from Amplification and Overexpression of &lt;i&gt;CTTN&lt;/i&gt; (&lt;i&gt;EMS1&lt;/i&gt;) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Figure S2 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation

Supplementary Figure S6 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Figure 2 from Amplification and Overexpression of <i>cttn</i> (<i>ems1</i>) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance

Supplementary Figure 3 from Amplification and Overexpression of <i>CTTN</i> (<i>EMS1</i>) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance